olverembatinib + chemotherapy

Olverembatinib + chemotherapy refers to a combination regimen in which **olverembatinib**, a third-generation tyrosine kinase inhibitor (TKI), is administered together with traditional **chemotherapy agents** for the treatment of hematological malignancies, particularly Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL)[5]. Olverembatinib acts by binding to the ATP-binding site of BCR-ABL1 and its mutants, including the resistant T315I variant, thereby inhibiting their kinase activity[2][4]. Combination with chemotherapy (such as low-dose chemotherapy regimens or specific agents like vincristine)[1][5] aims to enhance antileukemic efficacy and improve molecular remission rates in newly diagnosed patients or those resistant to prior therapies.